Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9945688 | 0.91 | ALDH1A1 (0.46) | ALDH1A1OPRM1OPRD1OPRK1CYP1A2 | |
| SCHEMBL11028956 | 0.91 | ALDH1A1 (0.46) | ALDH1A1OPRM1OPRD1OPRK1CYP1A2 | |
| SCHEMBL13652974 | 0.88 | OPRM1 (0.37) | ALDH1A1OPRM1OPRD1OPRK1CYP1A2 | |
| SCHEMBL12039787 | 0.88 | OPRM1 (0.37) | ALDH1A1OPRM1OPRD1OPRK1CYP1A2 | |
| SCHEMBL9945711 | 0.87 | ALDH1A1 (0.33) | ALDH1A1CYP1A2CYP2C9CYP2D6CYP2C19 | |
| SCHEMBL16281486 | 0.85 | LMNA (0.34) | ALDH1A1CYP1A2CYP2C9CYP2D6CYP2C19 | |
| SCHEMBL20996669 | 0.84 | CYP1A2 (0.33) | CYP1A2CYP2C9CYP2D6CYP2C19NPSR1 | |
| SCHEMBL13143549 | 0.84 | CYP1A2 (0.47) | ALDH1A1OPRM1OPRD1OPRK1CYP1A2 | |
| SCHEMBL7933716 | 0.84 | CYP1A2 (0.39) | ALDH1A1CYP1A2CYP2C9CYP2D6CYP2C19 | |
| SCHEMBL97470 | 0.83 | MAPT (0.42) | ALDH1A1CYP1A2CYP2C9CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293706-A1 | Multicomponent Delivery Systems for Polyanionic Cargo Compound Delivery | MEDICI THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2023141576-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS | POSEIDA THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| US-11701434-B2 | Tertiary amino lipidated cationic peptides for nucleic acid delivery | NUTCRACKER THERAPEUTICS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11697804-B2 | Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-07-11 | — | — | US | disclosed |
| US-20220040331-A1 | COMPOSITIONS AND METHODS FOR TRANSFECTING CELLS | AMRYT RESEARCH LIMITED (IE) | 2022-02-10 | — | — | US | disclosed |
| WO-2021081495-A1 | POLYMERIC NANOPARTICLES FOR INTRACELLULAR PROTEIN DELIVERY | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-04-29 | — | — | WO | disclosed |
| US-20180111905-A1 | N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2018-04-26 | — | — | US | disclosed |
| US-9884118-B2 | Multicomponent degradable cationic polymers | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-02-06 | — | — | US | disclosed |
| US-20170143639-A1 | NANOCOMPOSITES OF GOLD AND POLYMERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-05-25 | — | — | US | disclosed |
| US-9193827-B2 | Poly(beta-amino alcohols), their preparation, and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-11-24 | — | — | US | disclosed |
| US-8992991-B2 | Multicomponent degradable cationic polymers | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-03-31 | — | — | US | disclosed |
| US-8889665-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-8673904-B2 | Epoxide inhibitors of cysteine proteases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-03-18 | — | — | US | disclosed |
| US-8562966-B2 | End-modified poly(beta-amino esters) and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-10-22 | — | — | US | disclosed |
| US-20120149630-A1 | END-MODIFIED POLY(BETA-AMINO ESTERS) AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149630-A1 | END-MODIFIED POLY(BETA-AMINO ESTERS) AND USES THEREOF | PARN, PARG, POLL | ALDH1A1 2664/4885OPRM1 1152/4885OPRD1 546/4885 |
| US-20230293706-A1 | Multicomponent Delivery Systems for Polyanionic Cargo Compound Delivery | MTREX, EXOSC5, KPNA6 | ALDH1A1 4262/4885OPRM1 3010/4885OPRD1 3748/4885 |
| US-20180111905-A1 | N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT | ALK, NPM1, EML4 | ALDH1A1 1803/4885OPRM1 1587/4885OPRD1 4351/4885 |
| US-20170143639-A1 | NANOCOMPOSITES OF GOLD AND POLYMERS | HNRNPL, HNRNPLL, ACSL3 | ALDH1A1 883/4885OPRM1 4548/4885OPRD1 3324/4885 |
| US-11701434-B2 | Tertiary amino lipidated cationic peptides for nucleic acid delivery | LNPEP, SLC7A1, APLNR | ALDH1A1 4814/4885OPRM1 3592/4885OPRD1 3706/4885 |
| US-11697804-B2 | Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy | POLRMT, HDGF, PCNP | ALDH1A1 3433/4885OPRM1 2803/4885OPRD1 2337/4885 |
| US-20220040331-A1 | COMPOSITIONS AND METHODS FOR TRANSFECTING CELLS | TK1, XPA, RNASE1 | ALDH1A1 3345/4885OPRM1 4335/4885OPRD1 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.